An Act Establishing A Task Force To Develop A State-wide Plan To Reduce Morbidity And Mortality Caused By Venous Thromboembolism.
Summary
SB 568 would amend the general statutes to create a task force charged with developing a statewide plan to reduce morbidity and mortality caused by venous thromboembolism (VTE). VTE includes conditions such as deep vein thrombosis and pulmonary embolism, which can be serious or fatal if not prevented or treated promptly. The bill is focused on planning and coordination rather than direct treatment mandates or funding programs.
The task force would be expected to study the issue and produce a statewide strategy for reducing VTE-related illness and death. While the bill text does not specify the task force’s membership, duties, or deadlines, the purpose suggests a public health policy effort to improve awareness, prevention, diagnosis, and care pathways across Connecticut.
Impact
If enacted, the bill would add a new statutory task force within state law and likely direct public health stakeholders to participate in developing recommendations for VTE prevention and response. It would not, on its face, create new clinical requirements for providers or insurers, but it could lead to future legislation, administrative guidance, or public health initiatives based on the task force’s findings. The affected parties would likely include the Department of Public Health, hospitals, clinicians, patient advocates, and other public health experts.
Sentiment
The available record shows no committee transcript discussion and no recorded yea or nay votes, only a public hearing tally sheet reserved for subject matter hearing use. Based on the bill’s purpose, the measure appears to be framed as a public health improvement effort with a preventive, noncontroversial goal. There is no evidence in the provided materials of organized opposition or support beyond the bill’s introduction by bipartisan sponsors.
Contention
No specific points of contention are documented in the provided materials. Potential areas of future debate, if the bill advanced, could include the task force’s composition, whether it should include clinicians and patient representatives, the scope of its mandate, reporting deadlines, and whether the state should commit resources to implement any recommendations. However, none of those issues are raised in the available text or vote history.